Table: Kubota Pharmaceutical Holdings -9-MTH group results (IFRS)
Nov 12 (Reuters)-
Kubota Pharmaceutical Holdings Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2021 Sep 30, 2020 Dec 31, 2021
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 38 mln 10 mln
(-73.5 pct)
Operating loss 1.91 loss 1.92 loss 2.90
Pretax loss 1.93 loss 1.87 loss 2.80
Net loss 1.93 loss 1.87 loss 2.80
EPS Basic loss 42.50 yen loss 44.11 yen loss 62.84 yen
EPS Diluted loss 42.50 yen loss 44.11 yen
Ann Div NIL NIL
-Q2 Div NIL NIL
-Q4 Div NIL NIL
NOTE - Kubota Pharmaceutical Holdings Co., Ltd..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4596.T
Recent news on Kubota Pharmaceutical Holdings
See all newsTable: Kubota Pharmaceutical Holdings 6-MTH group results (IFRS)
Table: Kubota Pharmaceutical Holdings -Q1 group results (IFRS)
Brief: Kubota Vision Signs Supply & Licensing Agreement With Laboratoires Kôl
Table: Kubota Pharmaceutical Holdings -2025 parent results
Table: Kubota Pharmaceutical Holdings -2025 group results (IFRS)